Envisagenics
PrivateLast Round
Series B
Jun 5, 2024
Total Funding Raised
$50.56M
Company Overview
Envisagenics is a biotechnology company that develops an AI-driven bioinformatics platform to accelerate the discovery and validation of novel RNA splicing-based drug targets for oncology and neurodegenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Envisagenics Comparables
Compare Envisagenics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Deep Genomics | 85% | |
| Panorama Medicine | 84% | |
| Anima Biotech | 81% |
Envisagenics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 5, 2024 | ||||
| Grant | Aug 2, 2022 | ||||
| Series A | Sep 29, 2021 | ||||
| Grant | Oct 23, 2019 | ||||
| Grant | May 22, 2018 | ||||
Seed | Nov 28, 2017 |
Key People
Founding team and executive leadership
Envisagenics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| Dynamk Capital | Series A, Seed |
| SV Angel | Seed |
| Dolby Family Ventures | Seed |
| NIH RADx | Grant |
| Jove Equity Partners | Grant |
| M12 - Microsoft's Venture Fund | Grant, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 13, 2025
Sudhir Rao appointed as new Chief Business Officer.
- Jun 5, 2024
$25M round led by Third Kind Venture Capital and Celgene.
Recent news
Latest coverage and updates
- partners_withSep 25, 2026
Envisagenics partners with Johnson & Johnson Co..
- is_developingSep 23, 2026
Envisagenics is developing precision cancer therapies on Sep 23rd '26.
Envisagenics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Envisagenics's valuation, stock price, and market status.
Is Envisagenics a public or private company?
Envisagenics is a private company.
What is the current stock price of Envisagenics?
Envisagenics is a private company with no public stock price. No recent secondary market data is available.
How much is Envisagenics worth (valuation)?
Valuation information for Envisagenics is not publicly available.
Can I buy Envisagenics stock?
Envisagenics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Envisagenics's last funding round?
Envisagenics's most recent funding round was Series B on June 5, 2024.
Who are the main investors in Envisagenics?
Key investors in Envisagenics include National Cancer Institute, Dynamk Capital, NIH RADx, Red Cell Partners, Third Kind Venture Capital.
Will Envisagenics IPO soon?
No public IPO plans have been announced for Envisagenics.
How can I track Envisagenics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Envisagenics's secondary market activity and sign up for updates.